Our research in this field addresses major unmet medical needs in cancer, infectious diseases, and chronic disorders by targeting complex and non-classical biological processes through innovative chemical strategies. We focus on expanding the druggable proteome and developing next-generation therapeutic modalities that go beyond conventional small molecules and biologics.

Targeting Challenging Signaling Pathways and Protein–Protein Interactions

A major research axis explores signal transduction pathways involving non-canonical and difficult-to-drug targets, including pseudokinases, complex protein–protein interactions (PPIs), and intrinsically disordered proteins. In this context, we investigate the pseudokinase Integrin-Linked Kinase (ILK) using an integrated combination of chemical biology, molecular modeling, and biophysical techniques, with the long-term goal of developing novel therapies for diabetes, cancer, and chronic kidney disease. In parallel, we study the HIF–HIF interaction as a new paradigm in the transcriptional regulation of hypoxia-responsive genes. This research line focuses on the design of peptides and peptidomimetics capable of disrupting this critical PPI, combining state-of-the-art computational drug design with peptide chemistry and heterocyclic synthesis. Additionally, we participate in medicinal chemistry programs targeting NIK, CPT1, and the development of fluorescent radiosensitizers.

Antibody-Recruiting Molecules and Synthetic Immunotherapy

Our group is also involved in developing antibody-recruiting molecules (ARMs) as an emerging immunotherapeutic strategy for cancer and infectious diseases. ARMs are bifunctional synthetic molecules composed of a target-binding terminus (TBT) that recognizes receptors on diseased cells and an antibody-binding terminus (ABT) that recruits endogenous antibodies present in the bloodstream. The formation of the ternary complex (target cell–ARM–antibody) activates immune-mediated mechanisms leading to selective target cell clearance without the need for prior immunization. This modular and fully synthetic approach provides a cost-effective, adaptable, and potentially safer alternative to monoclonal antibody therapies, enabling the development of tailor-made treatments for diverse oncological and infectious indications.

Recent publications: